• Pact Group CEO and MD Malcolm Bundey.
    Pact Group CEO and MD Malcolm Bundey.
Close×

Pact Group's push into contract manufacturing has been further strengthened by the acquisition of aerosol manufacturer Pascoe's Group.

Pact Group Holdings has acquired Pascoe’s for $41 million.

The group’s investment in specialised contract manufacturing has recently included Jalco and Australian Pharmaceutical Manufacturers.

Based in Sydney, Pascoe’s manufactures both branded and private label products on behalf of key customers, in addition to the manufacture and distribution of a number of owned brands.

Pact Group’s MD and CEO Malcolm Bundey, said the acquisition would provide capability in aerosol-based products and  extend Pact's capability within liquids filling, providing alignment with the Jalco business.

“The team at Pascoe’s have strong technical knowledge and a demonstrated commitment to research and development," Bundey said. 

In other news for Pact Group, it recently appointed Charmaine England to the newly created position of executive general manager of contract manufacturing.

England most recently held the position of managing director at the Lion-owned Daily Drinks Company following a highly successful career with Unilever in both Australia and overseas.

Food & Drink Business

Australian drinks company, Casella Family Brands (CFB), has shifted the focus of its spirits strategy, making moves to bring Morris Whisky distribution in-house, expanding into global travel retail, and partnering with Proof Drinks Australia to handle its on-premise distribution.

The Australian Competition and Consumer Commission (ACCC) has appointed Sarah Proudfoot as its new chief executive officer, after Scott Gregson departed to take up the role of CEO at the Australian Securities and Investments Commission.

The latest data from IWSR has shown the pace of innovation in the expanding global RTD market is slowing, as brand owners focus their efforts on growth areas including spirit-based products, premium-plus price tiers and higher-ABV variants.